Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596514 | 0.94 | OPRK1 (0.39) | PLA2G4AACHEFAAHSIGMAR1BCHE | |
| SCHEMBL3592557 | 0.93 | SIGMAR1 (0.40) | EPHX2ACHEFAAHSIGMAR1BCHE | |
| SCHEMBL3595332 | 0.92 | LGALS1 (0.35) | ACHEFAAHMAOAMAPT | |
| SCHEMBL3598580 | 0.92 | MAPT (0.39) | ACHEFAAHSIGMAR1BCHEALOX5 | |
| SCHEMBL3598299 | 0.91 | HRH1 (0.39) | ACHEFAAHBCHEALOX5MAOA | |
| SCHEMBL3592076 | 0.91 | SIGMAR1 (0.41) | ACHEFAAHSIGMAR1BCHEALOX5 | |
| SCHEMBL3589423 | 0.90 | MAOA (0.39) | ACHEFAAHMAOAMAPTPKM | |
| SCHEMBL3596933 | 0.90 | PTGDR (0.39) | ACHESIGMAR1BCHEALOX5MAOA | |
| SCHEMBL3586655 | 0.89 | BCHE (0.38) | PLA2G4AACHESIGMAR1BCHEMAPK1 | |
| SCHEMBL13282376 | 0.89 | SIGMAR1 (0.39) | ACHEFAAHSIGMAR1BCHEALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | EPHX2 1055/4885PLA2G4A 2410/4885FFAR4 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.